Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuterol eMDPI in Asthma Exacerbations
NCT02969408Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of albuterol spiromax in asthma, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Clinical Asthma Exacerbation Rate at 12 weeks, Total Number of Inhalations in the Days Preceding the Peak of a Severe CAE at 12 weeks and 2 more. Started Feb 2017; status: completed.
02
Drugs
albuterol spiromax
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02969408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969408.